Evidence map›Paper›PMID 42315110›Full record

ArticleClinical genetics2026

USP34 Haploinsufficiency as a Cause of Neurodevelopmental Phenotypes.

Helena Wigoda, Amjad Khan, Bryce A Mendelsohn, Noriko Miyake, Nobuhiko Okamoto, Naomichi Matsumoto, Patricia J C Knijnenburg, Johanna M van Hagen, Jiddeke van de Kamp, Quinten Waisfisz and 1 more

Abstract read
In one paragraph

Article in Clinical genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Helena WigodaDepartment of Pediatrics, Center for Precision Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
Amjad KhanDepartment of Zoology, Institute of Biological Sciences, University of Lakki Marwat, Lakki Marwat, Khyber Pakhtunkhwa, Pakistan.ORCID https://orcid.org/0009-0001-8534-7921
Bryce A MendelsohnDepartment of Medical Genetics, Kaiser Permanente Oakland Medical Center, Oakland, California, USA.ORCID https://orcid.org/0000-0001-8174-5116
Noriko MiyakeDepartment of Pediatrics, Nagasaki University Institute of Biomedical Sciences, Nagasaki, Japan.
Nobuhiko OkamotoDepartment of Medical Genetics, Osaka Women's and Children's Hospital, Izumi, Osaka, Japan.
Naomichi MatsumotoDepartment of Human Genetics, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.ORCID https://orcid.org/0000-0001-9846-6500
Patricia J C KnijnenburgDepartment of Human Genetics, Amsterdam UMC, Amsterdam, the Netherlands.
Johanna M van HagenDepartment of Human Genetics, Amsterdam UMC, Amsterdam, the Netherlands.
Jiddeke van de KampDepartment of Human Genetics, Amsterdam UMC, Amsterdam, the Netherlands.
Quinten WaisfiszDepartment of Human Genetics, Amsterdam UMC, Amsterdam, the Netherlands.
Bryn D WebbDepartment of Pediatrics, Center for Precision Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.ORCID https://orcid.org/0000-0001-6174-4677

Funding

University of Wisconsin School of Medicine and Public Health Center for Precision MedicineUniversity of Wisconsin School of Medicine and Public Health Department of Pediatrics
6 · The paper itself

Abstract

The 2p15p16.1 microdeletion syndrome is a rare neurodevelopmental disorder caused by heterozygous deletions of variable size involving multiple dosage-sensitive genes. Within the narrowed critical interval, USP34 has emerged as a particularly strong candidate for the core phenotype, supported by reports of smaller deletions involving only USP34 and XPO1, and by the fact that USP34 encodes a deubiquitinating enzyme that stabilizes Axin and thereby regulates canonical Wnt/β-catenin signaling, a pathway critical for neurodevelopment, craniofacial morphogenesis, and limb patterning. We report six individuals with heterozygous loss-of-function variants in USP34, including five with confirmed de novo variants, associated with global developmental delay, craniofacial dysmorphism, marked speech impairment, variable autism spectrum disorder, and distal limb anomalies. The phenotype associated with isolated loss of USP34 overlaps substantially with that reported in 2p15p16.1 microdeletion syndrome, while suggesting that some features seen in larger deletions may reflect the contribution of additional genes within the interval. These findings support haploinsufficiency of USP34 as sufficient to cause a distinct neurodevelopmental disorder, establish USP34 as a major contributor to the neurodevelopmental and dysmorphic phenotype associated with the 2p15p16.1 locus, and refine gene-specific contributions within this microdeletion syndrome.

Indexed as

HaploinsufficiencyNeurodevelopmental DisordersUbiquitin-Specific ProteasesChildChild, PreschoolChromosome DeletionChromosomes, Human, Pair 2Developmental DisabilitiesFemaleGenetic Association StudiesHumansMaleNeurodevelopmentPhenotypeUbiquitin-Specific ProteasesUSP34 protein, human2p15p16.1 microdeletion syndromeautism spectrum disorderdevelopmental delayneurodevelopmental disorderUSP34

Identifiers

PMID42315110
PMCPMC13432289

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.